Home > Insider Trading > Filing (0000899243-21-034455)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1029142	Dynavax Technologies Corp	DVAX	Pharmaceutical Preparations (2834)	330728374

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657434	F. A. Andrew Hack	C/O Bain Capital Life Sciences Investors 200 Clarendon Street Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-08-27	1,891,000	$0.00	10,415,000	No	4	C	Indirect	See footnotes
Common Stock	Disposition	2021-08-27	2,000,000	$16.22	8,415,000	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-08-27	1,891	$0.00	1,891,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2019-08-12		No	4	C	Indirect

Footnotes

Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Each share of Series B Convertible Preferred Stock was convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and had no expiration date. The Series B Convertible Preferred Stock was not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion. On August 27, 2021, the Bain Capital Life Sciences Entities converted an aggregate of 1,891 shares of Series B Convertible Preferred Stock into an aggregate of 1,891,000 shares of the Issuer's common stock.